These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17458792)

  • 1. First clinical experience with anecortave acetate (Retaane).
    Hayek S; Scherrer M; Barthelmes D; Fleischhauer JC; Kurz-Levin MM; Menghini M; Helbig H; Sutter FK
    Klin Monbl Augenheilkd; 2007 Apr; 224(4):279-81. PubMed ID: 17458792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration.
    Augustin AJ; D'Amico DJ; Mieler WF; Schneebaum C; Beasley C
    Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):9-12. PubMed ID: 15290154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
    Slakter JS; Bochow TW; D'Amico DJ; Marks B; Jerdan J; Sullivan EK; Robertson SM; Slakter JS; Sullins G; Zilliox P;
    Ophthalmology; 2006 Jan; 113(1):3-13. PubMed ID: 16368146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes.
    Russell SR; Hudson HL; Jerdan JA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S79-90. PubMed ID: 17240260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration.
    Aggermann T; Haas P; Binder S
    Ann Ophthalmol (Skokie); 2008; 40(1):28-30. PubMed ID: 18556978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.
    D'Amico DJ; Goldberg MF; Hudson H; Jerdan JA; Krueger DS; Luna SP; Robertson SM; Russell S; Singerman L; Slakter JS; Yannuzzi L; Zilliox P;
    Ophthalmology; 2003 Dec; 110(12):2372-83; discussin 2384-5. PubMed ID: 14644721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Schmidt-Erfurth U; Michels S; Michels R; Aue A
    Eur J Ophthalmol; 2005; 15(4):482-5. PubMed ID: 16001382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration.
    Regillo CD; D'Amico DJ; Mieler WF; Schneebaum C; Beasley CH; Sullins GT
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S70-8. PubMed ID: 17240259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.
    D'Amico DJ; Goldberg MF; Hudson H; Jerdan JA; Krueger S; Luna S; Robertson SM; Russell S; Singerman L; Slakter JS; Sullivan EK; Yannuzzi L; Zilliox P;
    Retina; 2003 Feb; 23(1):14-23. PubMed ID: 12652226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
    Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV; Steén B; Seregard S; Kvanta A
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study.
    Klais CM; Eandi CM; Ober MD; Sorenson JA; Sadeghi SN; Freund KB; Spaide RF; Slakter JS; Yannuzzi LA
    Retina; 2006 Sep; 26(7):773-9. PubMed ID: 16963850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal triamcinolone acetonide for serous retinal pigment epithelial detachments in exudative age-related macular degeneration.
    Sutter FK; Kurz-Levin MM; Scherrer M; Barthelmes D; Fleischhauer JC; Helbig H
    Klin Monbl Augenheilkd; 2007 Apr; 224(4):297-9. PubMed ID: 17458796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
    Retina; 2007; 27(4):439-44. PubMed ID: 17420695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posterior juxtascleral depot administration of anecortave acetate.
    Kaiser PK; Goldberg MF; Davis AA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S62-9. PubMed ID: 17240258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration.
    Unver YB; Yavuz GA; Bekiroğlu N; Presti P; Li W; Sinclair SH
    Eye (Lond); 2009 Feb; 23(2):453-60. PubMed ID: 19039333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
    Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
    Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.